## CRM: Salesforce, Inc. - XLK: Technology

### Executive Summary

VALUE thesis: PEG 1.24 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (32% of avg), momentum weakening (-2.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($254.37)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Is Salesforce, Inc. (CRM) the most undervalued tech giant to buy?**
- Source: MSN | 20251229T143618 | Bullish | Relevance: 100%
- This article evaluates whether Salesforce, Inc. (CRM) is an undervalued technology giant, assessing its potential as a buying opportunity. It likely delves into financial metrics, market position, and growth prospects to support its argument regarding the company's valuation.

**2. Is Salesforce, Inc. (CRM) The Most Undervalued Tech Giant to Buy?**
- Source: Insider Monkey | 20251229T140737 | Bullish | Relevance: 100%
- Salesforce, Inc. (CRM) is considered an undervalued tech giant by hedge funds due to its potential for a rally as AI-related concerns ease and management focuses on profitability. Analysts like Oakmark Funds' Bill Nygren and BTIG's Allan Verkhovski support this view, with Mizuho setting a price target of $340, implying a 28% upside. Despite some concerns, its Agentforce momentum and compelling valuation at less than 14x CY27E FCF attract a 'Buy' rating from 78% of analysts.

**3. Salesforce (CRM) Stock Today: Weekend Headlines, Analyst Price Targets, and What to Watch Before Monday’s Market Open**
- Source: ts2.tech | 20251228T191312 | Somewhat-Bullish | Relevance: 100%
- Salesforce (CRM) is entering the final trading days of 2025 with a mix of bullish long-term analyst price targets and questions about converting its AI momentum into revenue. Recent headlines focus on institutional positioning shifts, new forecast write-ups, and the company's emphasis on AI reliability. Investors are keenly watching how macro factors, sector flows, AI sentiment, and the company's ability to translate Agentforce adoption into revenue acceleration will impact CRM stock as 2026 begins.

**4. Jim Cramer Says He Is "Not Quite Ready Yet to Give Up on Some of These Companies Like Salesforce"**
- Source: Finviz | 20251228T163143 | Bullish | Relevance: 100%
- Jim Cramer discussed Salesforce (NYSE: CRM) and its potential in the AI space, noting that despite fears of customers developing their own software, he's "not quite ready yet to give up" on the company. He highlighted the success of Salesforce's Agentforce AI platform, which has already hit a $500 million run rate and could redefine the company. Cramer was bullish on the company's latest quarterly performance, emphasizing the transformative potential of Agentforce for customer service.

**5. Novartis Selects ​Salesforce’s (CRM) Agentforce Life Sciences for Customer Engagement**
- Source: Insider Monkey | 20251228T105800 | Bullish | Relevance: 100%
- Novartis has chosen Salesforce’s Agentforce Life Sciences for Customer Engagement to enhance interactions with patients and healthcare professionals globally. This expands on Novartis's existing investments in Salesforce products, aiming to unify customer engagement across various departments like marketing, sales, and medical affairs over the next five years. Wall Street analysts are bullish on Salesforce, with recent "Buy" ratings and price targets as high as $340, citing the company's platform re-architecture and projected double-digit subscription revenue growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 7)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | BTIG | $335 | $0 | 0% |
| 2025-12-09 | Morgan Stanley | $398 | $405 | -2% |
| 2025-12-08 | Citigroup | $257 | $253 | +2% |
| 2025-12-05 | DA Davidson | $235 | $225 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | BTIG | init | Buy |
| 2025-12-09 | Morgan Stanley | main | Overweight |
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-05 | DA Davidson | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($26.61M) |
| Sells | 36 ($1.10M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.8%)
- Blackrock Inc.: 8.7% (-0.5%)
- State Street Corpora: 5.3% (+0.3%)
- JPMORGAN CHASE & CO: 2.8% (+46.5%)
- Geode Capital Manage: 2.2% (+0.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 6 raises (avg +4%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.24 suggests fair value with growth premium. Quality metrics strong (margin 18%). Balance sheet: $2.2B free cash flow. Analyst sentiment negative (7 target cuts vs 6 raises). Insider buying signal ($26.6M), management confidence. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $253.5B |
| Beta | 1.25 |
| 52W Range | $221.96 - $367.09 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.24 |
| Forward P/E | 20.3 |
| Current P/E | 22.6 |
| YoY Growth | 11.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.5% to 3.4% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.6pp (needs >4.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. AM_20 at 3.8% shows strong absolute momentum above own 20MA. Outperforming sector by 3.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.79), confirming momentum. Volume at 32% of 20MA suggests lack of conviction. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.40% (CS: 88) | Neutral |
| RSI_14 | 65.5 | Neutral |
| MACD Histogram | 0.79 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.035x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $266.25
- **Stop Loss:** $254.37 (4.5% risk)
- **Target:** $290.01 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 96
- **Position Value:** $25,560.00
- **Portfolio %:** 25.56%
- **Risk Dollars:** $1,150.00
- **Risk Per Trade:** 1.15%
- **Modifiers:** L1 115% | L2 100% | Combined 1.15x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-25 (Est: $3.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.86 | $3.25 | +13.6% |
| 2025Q3 | $2.78 | $2.91 | +4.7% |
| 2025Q2 | $2.55 | $2.58 | +1.3% |
| 2025Q1 | $2.61 | $2.78 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*